Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · see citing works

SIFT: predicting amino acid changes that affect protein function

Ng, P. C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg509 · Cited by 6,601 · see citing works

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,181 · see citing works

The World Health Organization (WHO) classification of the myeloid neoplasms

Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,191 · see citing works

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580 · see citing works

PI3K in lymphocyte development, differentiation and activation

Okkenhaug, K., & Vanhaesebroeck, B. (2003) · Nature reviews. Immunology · doi:10.1038/nri1056 · Cited by 812 · see citing works

Amino Acid Properties and Consequences of Substitutions

Betts, M. J., & Russell, R. B. (2003) · doi:10.1002/0470867302.ch14 · Cited by 490 · see citing works

Mechanism of action of lenalidomide in hematological malignancies

Kotla, V., Goel, S., Nischal, S., Heuck, C. J., Vivek, K., Das, B. C., & Verma, A. K. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-36 · Cited by 466 · see citing works

<i>TP53</i> Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8576 · Cited by 463 · see citing works

Amino‐Acid Properties and Consequences of Substitutions

Betts, M. J., & Russell, R. B. (2007) · doi:10.1002/9780470059180.ch13 · Cited by 452 · see citing works

Physiological functions of protein kinase B/Akt

Yang, Z., Tschopp, O., Baudry, A., Dummler, B. A., Hynx, D., & Hemmings, B. A. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320350 · Cited by 286 · see citing works

Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

Sujobert, P. (2005) · Blood · doi:10.1182/blood-2004-08-3225 · Cited by 243 · see citing works

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

Pellagatti, A., Armstrong, R. N., Steeples, V., Sharma, E., Repapi, E., Singh, S., Sanchi, A., Radujkovic, A., Horn, P., Dolatshad, H., et al. (2018) · Blood · doi:10.1182/blood-2018-04-843771 · Cited by 240 · see citing works

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

Sekeres, M. A., Othus, M., List, A. F., Odenike, O., Stone, R. M., Gore, S. D., Litzow, M. R., Buckstein, R., Fang, M., Roulston, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2510 · Cited by 237 · see citing works

The novel mechanism of lenalidomide activity

Fink, E. C., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-07-567958 · Cited by 213 · see citing works

Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome

Kennedy, J. A., & Ebert, B. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0806 · Cited by 170 · see citing works

Phosphoinositide-specific phospholipase C in health and disease

Cocco, L., Follo, M. Y., Manzoli, L., & Suh, P.-G. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r057984 · Cited by 165 · see citing works

Myelodysplastic syndromes current treatment algorithm 2018

Steensma, D. P. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0085-4 · Cited by 159 · see citing works

Clonal evolution in myelodysplastic syndromes

da Silva-Coelho, P., Kroeze, L. I., Yoshida, K., Koorenhof‐Scheele, T. N., Knops, R., van de Locht, L. T., de Graaf, A. O., Massop, M., Sandmann, S., Dugas, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15099 · Cited by 150 · see citing works

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia

Rothenberg‐Thurley, M., Amler, S., Görlich, D., Köhnke, T., Konstandin, N. P., Schneider, S., Sauerland, M. C., Herold, T., Hubmann, M., Ksienzyk, B., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0034-z · Cited by 139 · see citing works

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

Unnikrishnan, A., Papaemmanuil, E., Beck, D., Deshpande, N., Verma, A., Kumari, A., Woll, P. S., Richards, L. A., Knezevic, K., Chandrakanthan, V., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.067 · Cited by 132 · see citing works

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

Sekeres, M. A., Tiu, R. V., Komrokji, R. S., Lancet, J. E., Advani, A. S., Afable, M. G., Englehaupt, R. K., Juersivich, J., Cuthbertson, D. D., Paleveda, J., et al. (2012) · Blood · doi:10.1182/blood-2012-06-434639 · Cited by 130 · see citing works

Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1

Dornan, G. L., Siempelkamp, B. D., Jenkins, M. L., Vadas, O., Lucas, C. L., & Burke, J. E. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617244114 · Cited by 127 · see citing works

Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells

Compagno, M., Wang, Q., Pighi, C., Cheong, T.-C., Meng, F.-L., Poggio, T., Yeap, L.-S., Karaca, E., Blasco, R. B., Langellotto, F., et al. (2017) · Nature · doi:10.1038/nature21406 · Cited by 126 · see citing works

Molecular characterization ofde novoPhiladelphia chromosome-positive acute myeloid leukemia

Konoplev, S. N., Yin, C. C., Kornblau, S. M., Kantarjian, H. M., Konopleva, M. Y., Andreeff, M., Lu, G. G., Zuo, Z., Luthra, R., Medeiros, L. J., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.701739 · Cited by 117 · see citing works

Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS

Follo, M. Y., Finelli, C., Mongiorgi, S., Clissa, C., Bosi, C., Testoni, N., Chiarini, F., Ramazzotti, G., Baccarani, M., Martelli, A. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907109106 · Cited by 114 · see citing works

Mutations of AKT3 are associated with a wide spectrum of developmental disorders including extreme megalencephaly

Alcantara, D., Timms, A. E., Gripp, K. W., Baker, L., Park, K., Collins, S., Cheng, C. V., Stewart, F. A., Mehta, S. G., Saggar, A. K., et al. (2017) · Brain · doi:10.1093/brain/awx203 · Cited by 113 · see citing works

Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy

Uy, G. L., Duncavage, E. J., Chang, G. S., Jacoby, M. A., Miller, C. A., Shao, J., Heath, S. C., Elliott, K., Reineck, T., Fulton, R. S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.282 · Cited by 105 · see citing works

Germline-activating mutations in PIK3CD compromise B cell development and function

Avery, D. T., Kane, A., Nguyen, T., Lau, A., Nguyen, A., Lenthall, H., Payne, K. J., Shi, W., Brigden, H., French, E., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20180010 · Cited by 103 · see citing works

Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes

Fili, C. C., Malagola, M., Follo, M. Y., Finelli, C., Iacobucci, I., Martinelli, G., Cattina, F., Clissa, C., Candoni, A., Fanin, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3540 · Cited by 69 · see citing works

Phosphoinositide-Phospholipase C β1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia

Follo, M. Y., Finelli, C., Clissa, C., Mongiorgi, S., Bosi, C., Martinelli, G., Baccarani, M., Manzoli, L., Martelli, A. M., & Cocco, L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3748 · Cited by 60 · see citing works

Protein kinase C involvement in cell cycle modulation

Poli, A., Mongiorgi, S., Cocco, L., & Follo, M. Y. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140128 · Cited by 59 · see citing works

Mutations and prognosis in myelodysplastic syndromes: karyotype‐adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model

Gangat, N., Mudireddy, M., Lasho, T. L., Finke, C. M., Nicolosi, M., Szuber, N., Patnaik, M. M., Pardanani, A. D., Hanson, C. A., Ketterling, R. P., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25064 · Cited by 58 · see citing works

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression

Pellagatti, A., Roy, S., Genua, C. D., Burns, A., McGraw, K. L., Valletta, S., Larráyoz, M. J., Fernández‐Mercado, M., Mason, J., Killick, S. B., et al. (2015) · Leukemia · doi:10.1038/leu.2015.129 · Cited by 57 · see citing works

Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification

Uni, M., Masamoto, Y., Sato, T., Kamikubo, Y., Arai, S., Hara, E., & Kurokawa, M. (2018) · Leukemia · doi:10.1038/s41375-018-0198-6 · Cited by 48 · see citing works

Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis

Jafari, P. A., Ayatollahi, H., Sadeghi, R., Sheikhi, M., & Asghari, A. (2018) · Hematology · doi:10.1080/10245332.2018.1471794 · Cited by 45 · see citing works

Long non-coding RNA FEZF1-AS1 promotes cell growth in multiple myeloma via miR-610/Akt3 axis

Li, Q., Chen, L., Hu, N., & Zhao, H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.094 · Cited by 43 · see citing works

Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia

Ricciardi, M. R., Mirabilii, S., Licchetta, R., Piedimonte, M., & Tafuri, A. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.05.002 · Cited by 40 · see citing works

Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes

Follo, M. Y., Finelli, C., Mongiorgi, S., Clissa, C., Chiarini, F., Ramazzotti, G., Paolini, S., Martinelli, G., Martelli, A. M., & Cocco, L. (2010) · Leukemia · doi:10.1038/leu.2010.266 · Cited by 37 · see citing works

PLCγ2 and PKC Are Important to Myeloid Lineage Commitment Triggered by M‐SCF and G‐CSF

Barbosa, C. M. V., Bincoletto, C., Barros, C. C., Ferreira, A. T., & Paredes‐Gamero, E. J. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24653 · Cited by 37 · see citing works

Nuclear phospholipase C signaling through type 1 IGF receptor and its involvement in cell growth and differentiation.

Faenza, I., Billi, A. M., Follo, M. Y., Fiume, R., Martelli, A. M., Cocco, L., & Manzoli, L. (2005) · PubMed · Cited by 37 · see citing works

Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment

Follo, M. Y., Russo, D., Finelli, C., Mongiorgi, S., Clissa, C., Filì, C., Colombi, C., Gobbi, M., Manzoli, L., Piazzi, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.300 · Cited by 36 · see citing works

The physiology and pathology of inositide signaling in the nucleus

Ramazzotti, G., Faenza, I., Fiume, R., Matteucci, A., Piazzi, M., Follo, M. Y., & Cocco, L. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22334 · Cited by 36 · see citing works

Nuclear inositide signaling and cell cycle

Ratti, S., Ramazzotti, G., Faenza, I., Fiume, R., Mongiorgi, S., Billi, A. M., McCubrey, J. A., Suh, P., Manzoli, L., Cocco, L., et al. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.10.008 · Cited by 35 · see citing works

An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes

Cocco, L., Finelli, C., Mongiorgi, S., Clissa, C., Russo, D., Bosi, C., Quaranta, M., Malagola, M., Parisi, S., Stanzani, M., et al. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.2ma1114-541r · Cited by 34 · see citing works

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications

Pellagatti, A., & Boultwood, J. (2016) · Advances in Biological Regulation · doi:10.1016/j.jbior.2016.08.001 · Cited by 33 · see citing works

Nuclear inositide signaling in myelodysplastic syndromes

Follo, M. Y., Mongiorgi, S., Finelli, C., Clissa, C., Ramazzotti, G., Fiume, R., Faenza, I., Manzoli, L., Martelli, A. M., & Cocco, L. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22483 · Cited by 32 · see citing works

Nuclear Inositide Signaling Via Phospholipase C

Ratti, S., Mongiorgi, S., Ramazzotti, G., Follo, M. Y., Mariani, G. A., Suh, P., McCubrey, J. A., Cocco, L., & Manzoli, L. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25894 · Cited by 32 · see citing works

Differential effects of Akt isoforms on somatic cell reprogramming

Tang, Y., Jiang, Z., Luo, Y., Zhao, X., Wang, L., Norris, C. E., & Tian, X. (2014) · Journal of Cell Science · doi:10.1242/jcs.150029 · Cited by 30 · see citing works

Nuclear translocation of PKC‐ α is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs)

Poli, A., Ratti, S., Finelli, C., Mongiorgi, S., Clissa, C., Lonetti, A., Cappellini, A., Catozzi, A., Barraco, M., Suh, P., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201700690r · Cited by 29 · see citing works

Puquitinib, a novel orally available PI 3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia

Xie, C., He, Y., Zhen, M., Wang, Y., Xu, Y., & Lou, L. (2017) · Cancer Science · doi:10.1111/cas.13263 · Cited by 28 · see citing works

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches

Armstrong, R. N., Steeples, V., Singh, S., Sanchi, A., Boultwood, J., & Pellagatti, A. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.09.008 · Cited by 27 · see citing works

Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation

Mongiorgi, S., Follo, M. Y., Yang, Y. R., Ratti, S., Manzoli, L., McCubrey, J. A., Billi, A. M., Suh, P., & Cocco, L. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160226132338 · Cited by 24 · see citing works

Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts

Mangaonkar, A. A., Gangat, N., Al‐Kali, A., Elliott, M. A., Begna, K. H., Hanson, C. A., Ketterling, R. P., Wolanskyj, A. P., Hogan, W. J., Litzow, M. R., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.07.010 · Cited by 22 · see citing works

Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy

Manzoli, L., Mongiorgi, S., Clissa, C., Finelli, C., Billi, A. M., Poli, A., Quaranta, M., Cocco, L., & Follo, M. Y. (2014) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557514666141013125936 · Cited by 21 · see citing works

Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment

Stosch, J. M., Heumüller, A., Niemöller, C., Bleul, S., Rothenberg‐Thurley, M., Riba, J., Renz, N., Szic, K. S. V., Pfeifer, D., Follo, M., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15461 · Cited by 19 · see citing works

Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes

Mongiorgi, S., Finelli, C., Yang, Y. R., Clissa, C., McCubrey, J. A., Billi, A. M., Manzoli, L., Suh, P., Cocco, L., & Follo, M. Y. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1125885 · Cited by 15 · see citing works

Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes

Finelli, C., Follo, M. Y., Stanzani, M., Parisi, S., Clissa, C., Mongiorgi, S., Barraco, M., & Cocco, L. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160310145040 · Cited by 15 · see citing works

Trends in Clinical Investigation for Myelodysplastic Syndromes

Prébet, T., & Zeidan, A. M. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.02.012 · Cited by 13 · see citing works

Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS

Ganster, C., Shirneshan, K., Salinas, G., Braulke, F., Schanz, J., Platzbecker, U., & Haase, D. T. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.06.011 · Cited by 11 · see citing works

Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics

Mongiorgi, S., Follo, M. Y., Clissa, C., Giardino, R., Fini, M., Manzoli, L., Ramazzotti, G., Fiume, R., Finelli, C., & Cocco, L. (2012) · Current topics in microbiology and immunology · doi:10.1007/978-94-007-5025-8_11 · Cited by 10 · see citing works

The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration

Jackson, J. T., Mulazzani, E., Nutt, S. L., & Masters, S. L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100905 · Cited by 113 · see citing works

Overarching roles of diacylglycerol signaling in cancer development and antitumor immunity

Cooke, M., & Kazanietz, M. G. (2022) · Science Signaling · doi:10.1126/scisignal.abo0264 · Cited by 92 · see citing works

Phospholipase C families: Common themes and versatility in physiology and pathology

Katan, M., & Cockcroft, S. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101065 · Cited by 89 · see citing works

Phosphoinositide-Dependent Signaling in Cancer: A Focus on Phospholipase C Isozymes

Obeng, E. O., Rusciano, I., Marvi, M. V., Fazio, A., Ratti, S., Follo, M. Y., Xian, J., Manzoli, L., Billi, A. M., Mongiorgi, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072581 · Cited by 85 · see citing works

Phospholipase Cγ2 regulates endocannabinoid and eicosanoid networks in innate immune cells

Jing, H., Reed, A., Ulanovskaya, O. A., Grigoleit, J.-S., Herbst, D. M., Henry, C. L., Li, H., Barbas, S., Germain, J., Masuda, K., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2112971118 · Cited by 24 · see citing works

Prediction of Alzheimer’s disease-specific phospholipase c gamma-1 SNV by deep learning-based approach for high-throughput screening

Kim, S.-H., Yang, S., Lim, K., Ko, E., Jang, H., Kang, M., Suh, P., & Joo, J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2011250118 · Cited by 27 · see citing works

The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications

Awada, H. K., Thapa, B., & Visconte, V. (2020) · Cells · doi:10.3390/cells9112512 · Cited by 24 · see citing works

Cryptic mutations of PLC family members in brain disorders: recent discoveries and a deep-learning-based approach

Lim, K.-H., Yang, S., Kim, S.-H., Ko, E., Kang, M., & Joo, J.-Y. (2023) · Brain · doi:10.1093/brain/awac451 · Cited by 21 · see citing works

Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment

Stosch, J. M., Heumüller, A., Niemöller, C., Bleul, S., Rothenberg‐Thurley, M., Riba, J., Renz, N., Szic, K. S. V., Pfeifer, D., Follo, M., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15461 · Cited by 19 · see citing works

Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes

Yang, Y., Li, J., Geng, Y., Liu, L., & Li, D. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23597 · Cited by 14 · see citing works

Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes

Xian, J., Obeng, E. O., Ratti, S., Rusciano, I., Marvi, M. V., Fazio, A., Stefano, A. D., Mongiorgi, S., Cappellini, A., Ramazzotti, G., et al. (2020) · Cells · doi:10.3390/cells9030697 · Cited by 14 · see citing works

Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia

Ratti, S., Mongiorgi, S., Rusciano, I., Manzoli, L., & Follo, M. Y. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118649 · Cited by 11 · see citing works

Recent advances in MDS mutation landscape: Splicing and signalling

Follo, M. Y., Pellagatti, A., Ratti, S., Ramazzotti, G., Faenza, I., Fiume, R., Mongiorgi, S., Suh, P., McCubrey, J. A., Manzoli, L., et al. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.100673 · Cited by 9 · see citing works

Phospholipase C beta1 (PI‐PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron‐induced oxidative stress in myelodysplastic syndromes (MDS)

Cappellini, A., Mongiorgi, S., Finelli, C., Fazio, A., Ratti, S., Marvi, M. V., Curti, A., Salvestrini, V., Pellagatti, A., Billi, A. M., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000933rr · Cited by 9 · see citing works

PLCG2 across human disease: genetic variants, signaling mechanisms, and clinical implications

Jiang, P., Wang, M., Zhang, C., Li, X., Wang, Z. Q., Guo, Y., Zhang, J., Yan, W., & Xi, X. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07632-7 · Cited by 6 · see citing works

Inositide-Dependent Nuclear Signalling in Health and Disease

Follo, M. Y., Ratti, S., Manzoli, L., Ramazzotti, G., Faenza, I., Fiume, R., Mongiorgi, S., Suh, P. G., McCubrey, J. A., & Cocco, L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_321 · Cited by 6 · see citing works

A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes

Mongiorgi, S., Stefano, A. D., Ratti, S., Indio, V., Astolfi, A., Casalin, I., Pellagatti, A., Paolini, S., Parisi, S., Cavo, M., et al. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01441-9 · Cited by 6 · see citing works

Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression

Casalin, I., Stefano, A. D., Ceneri, E., Cappellini, A., Finelli, C., Curti, A., Paolini, S., Parisi, S., Zannoni, L., Boultwood, J., et al. (2024) · Advances in Biological Regulation · doi:10.1016/j.jbior.2024.101014 · Cited by 6 · see citing works

“Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia”

Ratti, S., Evangelisti, C., Mongiorgi, S., Stefano, A. D., Fazio, A., Bonomini, F., Follo, M. Y., Faenza, I., Manzoli, L., Sheth, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.678824 · Cited by 6 · see citing works

Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation

Liang, D., Wei, C., Zhang, X., Yang, J., Zheng, Y., Du, J., Wang, L., & Deng, L. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1919665 · Cited by 4 · see citing works

Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome

Niederwieser, C., & Kröger, N. M. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101332 · Cited by 5 · see citing works

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes

Kim, S., Shin, D., Kim, D., Oh, S., Hong, J., Kim, I., & Kim, E. J. (2021) · Cells · doi:10.3390/cells10123494 · Cited by 4 · see citing works

Multi-omics analysis of multiple myeloma patients with differential response to first-line treatment

Zheng, B., Yi, K., Zhang, Y., Pang, T., Zhou, J.-Y., He, J., Lan, H., Xian, H., & Li, R. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01148-4 · Cited by 4 · see citing works

Advances in MDS/AML and inositide signalling

Stefano, A. D., Marvi, M. V., Fazio, A., McCubrey, J. A., Suh, P., Ratti, S., Ramazzotti, G., Manzoli, L., Cocco, L., & Follo, M. Y. (2023) · Advances in Biological Regulation · doi:10.1016/j.jbior.2023.100955 · Cited by 2 · see citing works

SMC2 and Condensin II Subunits Are Essential for the Development of Hematopoietic Stem and Progenitor Cells in Zebrafish

Oh, C., Kim, M. S., Shin, U., Kang, J. W., Kim, Y. H., Ko, H. S., Ra, J. S., Ahn, S., Choi, E. Y., Yu, S., et al. (2025) · Journal of Cellular Physiology · doi:10.1002/jcp.70023 · Cited by 1 · see citing works

Survival of myelodysplastic syndrome patients after azacitidine therapy

Thammagul, K., Limpiwattakee, S., Chantrathammachart, P., Puavilai, T., Chuncharunee, S., & Niparuck, P. (2026) · BMC Cancer · doi:10.1186/s12885-026-15997-1 · Cited by 1 · see citing works

Physiological Roles of Phospholipase Cγ and Its Mutations in Human Disease

Jang, H., Choi, J. H., & Chang, J. (2020) · Scholarworks@UNIST (Ulsan National Institute of Science and Technology) · doi:10.5352/jls.2020.30.9.826

Crosstalk between phospholipases and noncoding RNAs in cancer

Baisakhiya, S., Nagaraja, S. S., & Nagarajan, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95698-7.00022-x

Relationship between phospholipases and LncRNAs during the onset of diseases

Bhagat, G. K., & Bagchi, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95698-7.00006-1

Phospholipases and their metabolites in cancer

Yadav, S., Mishra, A., Mishra, S. N., Kumar, R., Vijayaraghavalu, S., & Kumar, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95697-0.00016-9

Generalized information criteria for personalized gene network inference

Park, H., Imoto, S., & Konishi, S. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1583756

Analysis of chromatin accessibility associated with azacitidine response in higher-risk myelodysplastic neoplasms

Kim, D., Park, S., Kwon, Y.-R., Yoon, H., Cho, B., Baek, I., Kang, J. H., Park, T.-E., Corces, M., Kim, H.-J., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113297 · Cited by 1 · see citing works

Inositide-dependent signal transduction in the nucleus: a virtuous path from the laboratory to the clinic

Stefano, A. D., McCubrey, J. A., Suh, P. G., Ramazzotti, G., Fiume, R., Ratti, S., Follo, M. Y., Manzoli, L., & Cocco, L. (2025) · Advances in Biological Regulation · doi:10.1016/j.jbior.2025.101142

Additional file 1 of A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes

Mongiorgi, S., Stefano, A. D., Ratti, S., Indio, V., Astolfi, A., Casalin, I., Pellagatti, A., Paolini, S., Parisi, S., Cavo, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26569921

Additional file 3 of A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes

Mongiorgi, S., Stefano, A. D., Ratti, S., Indio, V., Astolfi, A., Casalin, I., Pellagatti, A., Paolini, S., Parisi, S., Cavo, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26569927

Additional file 2 of A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes

Mongiorgi, S., Stefano, A. D., Ratti, S., Indio, V., Astolfi, A., Casalin, I., Pellagatti, A., Paolini, S., Parisi, S., Cavo, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26569924

SRSF2 mutations drive daunorubicin resistance in acute myeloid leukemia via THBS1 stabilization

Wu, Y., Wu, X., Tang, Y., Zhang, Y., Du, Y., Yang, K., Yang, Y., & Gong, Y. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03649-y

Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Follo, M. Y., Pellagatti, A., Armstrong, R. N., Ratti, S., Mongiorgi, S., Astolfi, A., Indio, V., Bochicchio, M. T., Clissa, C., Russo, D., et al. (2018) · Blood · doi:10.1182/blood-2018-99-112062

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes

Cedena, M., Rapado, I., Santos‐Lozano, A., Ayala, R. M., Onecha, E., Abáigar, M., Such, E., Ramos, F., Cervera, J., Díez‐Campelo, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22157 · Cited by 42 · see citing works

Mutations in DNA Methylation Pathway and Number of Driver Mutations Predict Response to Azacitidine in Myelodysplastic Syndromes

Cedena, M., Rapado, I., Santos‐Lozano, A., Ayala, R. M., Onecha, E., Abáigar, M., Such, E., Ramos, F., Cervera, J., Sanz, G. F., et al. (2017) · Leukemia Research · doi:10.1016/s0145-2126(17)30210-2 · Cited by 6 · see citing works

Azacitidine Combination with Lenalidomide in Treating Higher-Risk Myelodysplastic Syndromes: A Single-Center, Phase 2 Trial

Song, D., & Ge, Z. (2023) · Blood · doi:10.1182/blood-2023-184735

Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna

FOLLO, M. Y., MONGIORGI, S., ASTOLFI, A., Indio, V., RATTI, S., Clissa, C., Barraco, M., Parisi, S., Manzoli, L., PESSION, A., et al. (2017) · Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)